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ABSTRACT 
Trabeculectomy surgery has been shown to lower intraocular pressure and is the most commonly 
performed glaucoma procedure worldwide. However, giving a patient a ‘bleb for life’ is not without 
consequences and the failure of trabeculectomy to control IOP in the long term is well documented. In 
some instances, such as in patients with exfoliative glaucoma or primary angle closure glaucoma, cataract 
surgery alone can often lower IOP to acceptable levels. Cataract surgery in these instances can sometimes 
be combined with procedures such as goniosynechialysis or endoscopic cyclophotocoagulation which may 
provide additional IOP lowering. Such surgery has the distinct advantage of avoiding conjunctival incisions, 
so that subsequent trabeculectomy, if required, is more likely to be successful. In any case, it is preferable 
to perform trabeculectomy in a pseudophakic eye for several reasons. If trabeculectomy is performed in a 
phakic eye, patients should be warned that subsequent cataract is likely and if cataract surgery is 
performed it is preferable to wait at least a year or more after the trabeculectomy to reduce the risk of 
bleb failure. Combined phacotrabeculectomy should be reserved for end-stage glaucoma in most cases, in 
order to reduce the risk of ‘wipe-out’.  
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INTRODUCTION 
Patients with cataracts and glaucoma are common in 
hospital clinics. There has been much published in recent 
years on how best to manage these subjects (1-4). This 
review will attempt to summarise the evidence and help 
the general ophthalmologist make informed decisions on 
management based on the available data.  
  As this review is intended for the general   
ophthalmologist, discussion will exclude aqueous 
drainage device implantation, non-penetrating glaucoma 
surgery and devices and procedures such as the Ex-Press 
shunt, the istent, canaloplasty etc. That is not because 
these procedures are without merit, but most general 
ophthalmologists, and indeed, many glaucoma 
specialists, will be less familiar with them. In addition, 
particularly for the latter procedures, long term data on 
efficacy and safety is pending. Essentially, in this context, 
glaucoma surgery refers to trabeculectomy. 
  As with all fields in medicine, management will depend 
on several factors and will have to be tailored to the 
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individual patient. Some factors that need to be assessed 
for all patients would be age, severity of visual field loss, 
intraocular pressure, rate of glaucomatous progression, 
type of glaucoma and degree of cataract growth. The aim 
of treatment is of course to improve quality of life which 
essentially means improving vision (cataract surgery) and 
slowing glaucomatous progression; these treatments 
must occur while causing the least discomfort and 
inconvenience to patients and by keeping complications 
and side effects to a minimum. 
  There are 3 principles that are useful in guiding 
clinicians as to the best management for these patients. 
These are: 
 1. Giving a patient a trabeculectomy bleb for life can be 
problematic and should be avoided if other options are 
available. 
2. Trabeculectomy surgery is not always necessary in 
order to lower IOP. 
3. If trabeculectomy is necessary, it is important to 
prime the eye to enable the best chance of success.  
  These 3 principles will be discussed further to provide 
evidence of their viability as treatment options and 
explore how they can help in making management 
decisions. 
 
Trabeculectomy surgery is associated with 
long-term problems and therefore should be 
avoided if possible.  
Modern cataract surgery is a relatively quick and safe 
procedure and therefore one can assume a good 
outcome in most cases. It is a one-off event, and if it is 
performed without complication, it is unlikely to result in 
further difficulties or morbidity (1-10). 
  Glaucoma surgery, specifically trabeculectomy, is 
different. Even if the procedure is performed without 
complication, future morbidity often does occur. The 
most obvious of these is loss of IOP control, or 
trabeculectomy failure. Rates for this vary according to 
the population studied (5) and the definition of failure, 
but can be as high as 84% at 3 years (6). It could be 
argued that if the trabeculectomy fails, the patient goes 
back to ‘square one’ and, other than the inconvenience 
caused, no harm is done. However, it is the experience of 
many surgeons that the IOP after a failed trabeculectomy 
is higher than the IOP before trabeculectomy, even if 
drops are re-started. There is some experimental data 
supporting this observation (7,8) and it is postulated that 
diversion of aqueous via the sclerostomy to the sub-
tenons space may compromise trabeculectomy 
meshwork functionality. There is good evidence that 
anterior chamber shallowing occurs after trabeculectomy 
and this lasts at least 5 years (9). This may result in 
mechanical closure of the angle (peripheral anterior 
synechiae or PAS), further compromising outflow via the 
conventional route. Therefore, to aver that a failed 
trabeculectomy constitutes ‘no harm done’ is likely to be 
incorrect 
  Bleb-related infections can occur years after 
trabeculectomy. The Collaborative Initial Glaucoma 
Treatment Study (CIGTS) found rates of blebitis of 1.5% 
and bleb-related endophthalmitis of 1.1% at 5 years (10). 
Other studies have found higher rates (11,12). In the 
contemporary setting, use of anti-metabolites is 
ubiquitous, such that the NICE guidelines from UK 
recommend anti-metabolite use for all subjects 
undergoing trabeculectomy. To achieve lower IOPs, 
longer duration of antimetabolite use intraoperatively is 
often required, leading to thinner blebs and higher risk if 
infection (13). The pertinent fact is that risk of blebitis 
never goes away and patients with thin walled blebs will 
need to be aware of the risk of infection for the rest of 
their lives, something that cataract surgery patients, as 
an example, need not worry about. Many surgeons will 
advise patients that have had trabeculectomy to avoid 
swimming and yoga for example. The assumption that 
for most of patients attending glaucoma clinics these 
pastimes are not relevant (because of age) is 
condescending and probably untrue. Restricting these 
activities can have a significant effect on quality of life, 
no matter how well intentioned the advice. 
  Dysesthesia is a common symptom reported following 
trabeculectomy and may indeed be under-reported as 
clinicians (and sometimes patients) tend to concentrate 
on IOP level – if IOP is low, the surgery is considered a 
success. In a prospective study of 97 subjects who had 
had trabeculectomy in one year, symptoms such as pain, 
discomfort, burning were significantly more common in 
the surgery eye compared to the fellow eye (dysesthesia 
score of 11.1 versus 3.4, p=0.005) (14). Similar findings 
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were reported in the CIGTS where patients reported 
significantly more local eye symptoms in the eye which 
had had trabeculectomy compared to the eye 
randomized to medications (15). 
  Ptosis, again from the CITGS, was found to occur in 12% 
of subjects in the trabeculectomy arm (16). A more 
recent study has found lid retraction to be a significant 
problem in some eyes that have had trabeculectomy 
(17). Both conditions can result in poor cosmesis and 
further surgery is sometimes required. 
  In summary, although trabeculectomy is performed to 
lower IOP, and frequently does do so in the short to 
medium term, longer term results are less satisfactory. 
The surgery is associated with significant and relatively 
common complications.Following the dictum of ‘primum 
non nocere’ i.e. first do no harm, surgeons need to 
consider very carefully before performing 
trabeculectomy. The conclusion is that other procedures 
should be considered, if appropriate. This leads on to the 
second principle. 
 
Trabeculectomy surgery is often not necessary 
in order to lower IOP 
Assuming that medical treatment is at a maximum 
tolerated level, there’s no doubt that trabeculectomy 
results in a lowering of the IOP, albeit not necessarily in 
the long term. Following the premise discussed above, 
are there any other ways to lower IOP without producing 
a trabeculectomy bleb?  
  In two specific instances, there is evidence that cataract 
surgery alone can lower IOP to satisfactory levels in a 
large proportion of cases. These are in patients with 
exfoliative glaucoma (XFG) and in patients with primary 
angle closure glaucoma (PACG).  
  Prevalence of XFG varies from region to region, with 
some evidence to suggest that it is more common in 
northern latitudes (18). In some countries, prevalence of 
XFG can account for more than half of cases of open 
angle glaucoma, and worldwide XFG is thought to 
account for 20-25% of open angle glaucoma (19). There is 
some evidence that performing cataract surgery in eyes 
with XFG results in reduced IOP, either alone (20) or if 
combined with trabecular aspiration (21,22). A large 
single surgeon series of phacoemulsification cataract 
surgery alone in eyes with exfoliation syndrome and XFG 
found a significant reduction in IOP at all-time points up 
to 7 years post-surgery (23). A later study published by 
the same group compared these findings with similar 
subjects that had undergone combined 
phacotrabeculectomy. They found the combined surgery 
group had lower IOP at 7 years (24). This suggests that in 
XFG patients, if low IOP is required, combined surgery 
may be preferable, but if a moderate reduction of IOP is 
all that is needed, cataract surgery alone may be 
sufficient. 
  For patients with PACG, the evidence that cataract 
surgery reduces IOP is more extensive. Tham et al. have 
published a series of high quality prospective studies 
examining this topic. Comparing phacoemulsification to 
trabeculectomy in eyes with medically uncontrolled 
PACG, they found no significant difference in IOP at two 
years between the groups, although the trabeculectomy 
group required less IOP-lowering medication (25). 
Complications in the latter group were significantly 
higher. Comparing phacoemulsification to combined 
phacotrabeculectomy in medically uncontrolled PACG 
subjects, they found although the combined surgical 
group had lower IOP at 18 months, the 
phacoemulsification group still had a significant 
reduction in IOP (mean IOP at 18 months was 
15.9mmHg) (26). Again, complications were higher in the 
combined surgical group. A similar study comparing 
phacoemulsification to phacotrabeculectomy in 
medically controlled PACG subjects found no difference 
in IOP between groups at 2 years (27). 
  If significant PAS is present, combining 
phacoemulsification with goniosynechialysis (phaco-GSL) 
has yielded promising results, although all studies 
published to date have been case-series. In the first 
prospective series on this procedure, Teekhasaenee et al. 
found in a series of 52 eyes, 90.4% had IOP less than 20 
mmHg without medications (28). In a more recent 
publication, Zhang et al. found that performing cataract 
extraction with visco-goniosynechialysis (phaco-VGSL) in 
subjects with medically uncontrolled IOP, mean IOP 
decreased from 45mmHg to 15 mmHg at 6 months in a 
series of 17 patients, without serious complication (29). 
These reductions are impressive for surgery which is 
relatively straightforward and which does not result in 
the creation of a filtration bleb. Indeed, Tang et al. 
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compared phaco-VGSL to trabeculectomy in a 
retrospective study of 39 eyes and found that, at 10 
months, IOP was lower in the phaco-VGSL group 
compared to the trabeculectomy group (14.1 vs 16.5 
mmHg, p=0.025) (30). The concern with phaco-GSL has 
always been that the IOP lowering effects may be 
temporary. A publication from March this year from 
Japan however, found IOP less than 21mmHg in 85.9% of 
subjects undergoing phaco-GSL at 3 years, suggesting 
that the procedure may have long term success (31). In 
fact, it seems credible that long term success should be 
achievable, since, once the cataract is removed, it is 
unlikely that the drainage angle should narrow again 
post-procedure, since the peripheral anterior chamber 
deepens after cataract extraction (32). The group from 
Japan supplemented phaco-GSL with post-operative laser 
iridoplasty, and found that this led to significantly better 
results. This is an interesting adjunct and hopefully 
further publications will establish the safety and efficacy 
of this. 
  These results suggest that in subjects with XFG or PACG, 
cataract surgery alone (especially if combined with GSL if 
indicated) can reduce IOP significantly (or adequately) in 
many cases. What about the largest group of patients 
seen in most glaucoma clinics, patients with POAG? The 
evidence that cataract surgery alone will reduce IOP 
significantly in these patients is weak or equivocal.  
Reviews from 2002 and 2010 reported that IOP 
decreasesaround 1.5 to 4.5mmHg after 
phacoemulsification in POAG subjects (1,33). The authors 
highlighted the importance of the statistical quirk known 
as ‘regression to the mean’ which may account for the 
supposed IOP reduction in many of the papers that were 
reviewed. Some clinicians have tried combining 
phacoemulsification surgery with endoscopic-
cyclophotocoagulation (phaco-ECP). There have been a 
few studies in the last few years showing reasonable 
results with this procedure. In a retrospective analysis of 
58 eyes from UK, IOP was reduced from 21.4mmHg to 
14.4mmHg, which was significant (34). In another series 
from the UK of 63 eyes a similar reduction was found: 
21.1mmHg to 15.1mmHg at 1 year and a significant 
reduction in the number of IOP-lowering medications 
(35). The results are moderately impressive although it is 
surprising that the procedure, with the technology 
having been around for so long, has not produced more 
data to support its effectiveness. 
  If IOP is not lowered enough after phacoemulsification 
alone, selective laser trabeculoplasty (SLT) can be 
performed.  This can sometimes result in significant 
lowering of IOP but the concern with SLT has always 
been that in some subjects there is minimal reduction 
and the effect of IOP lowering tends to decrease with 
time; although the laser can be repeated. SLT reduces 
IOP by approximately 18-40% (36), which may be 
sufficient in some patients. Several publications have 
examined the effectiveness of SLT in pseudophakic 
subjects with reduction of IOP of around 4mmHg or 25% 
depending on the study (37,38). 
  The conclusion of this section is that cataract surgery 
alone (with GSL if need be) can certainly reduce IOP, 
sometimes to the low teens, particularly in subjects with 
XFG or PACG. Even if low teens IOPs are not achieved, it 
must be recognised that not all patients with glaucoma 
will require this level of IOP reduction. If cataract surgery 
alone (or combined with ECP) can reduce IOP to a 
degree, and even if IOP-lowering drops (or SLT) are 
necessary to lower IOP further, this still may be 
preferable to the patient having a trabeculectomy bleb. 
For those patients with more advanced glaucoma, or 
who need lower IOP, they may indeed require a 
subsequent trabeculectomy. If this is the case, at least a 
proportion of patients will be able to avoid having a 
trabeculectomy bleb. In addition, performing 
trabeculectomy in an eye which has already had cataract 
surgery may be preferable to performing trabeculectomy 
on a phakic eye, or performing combined 
phacotrabeculectomy. This will be discussed in the next 
section. 
 
If trabeculectomy is necessary, it is important 
to plan the surgery to give the best chance of 
success.  
In many cases, of course, trabeculectomy surgery is 
necessary in order to achieve the low IOP levels that are 
needed to reduce the risk of further glaucomatous loss. It 
is important to operate under the conditions which will 
give the filtering bleb the best chance of maintaining a 
low IOP in the long term. As explained in the 
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introduction, trabeculectomy is a half hour procedure 
and yet we expect its effectiveness to last for several 
years.  The operation must therefore be performed 
under the most optimal conditions possible in order to 
ensure long-term success.  In patients with cataract and 
medically uncontrolled glaucoma, the options are to 
perform trabeculectomy first then cataract surgery, 
cataract surgery first and then trabeculectomy, or to 
combine the surgery (phacotrabeculectomy).  
  In cases of XFG or PACG, the evidence suggests that it is 
preferable in most cases to perform cataract surgery first 
as, as has been shown in the section above. In many 
cases this will reduce IOP sufficiently so that glaucoma 
surgery is not necessary. In cases of PACG, the main 
cause for the high IOP is postulated to be obstruction of 
aqueous outflow due to a crowded anterior chamber. 
Taking out the cataract (or even the clear lens) will 
reduce this crowding and hence addresses the (probable) 
cause for the high IOP (32). When cataract surgery is 
performed, the surgeon should avoid making 
conjunctival incisions (e.g. sub-tenon’s anaesthesia) as 
this has been shown to increase subsequent 
trabeculectomy failure due to ‘priming’ of fibroblasts 
(39). This priming is thought to occur even if the 
conjunctival incisions are made away from the site of the 
subsequent trabeculectomy surgery. There are good 
clinical data also to support this idea. In a study from 
1991, 66 subjects that had trabeculectomy were 
examined and risk factors for failure were entered into a 
multiple regression model. Formerconjunctival incisional 
surgery was associated with failure at 3 years (40). A 
later study by Broadway and Hitchings found success at 6 
years after trabeculectomy was 93% in a control group 
versus 38% in a group that had had previous conjunctival 
incisional surgery (p<0.001) (41). Histological 
examination of the conjunctiva from the latter group 
found a significantly higher proportion of fibroblasts.  
Fontana et al. published two separate papers in 2006, 
which, if compared, have interesting findings. The first 
paper was a retrospective analysis of 89 eyes with open 
angle glaucoma which had had previous cataract surgery 
and then had trabeculectomy with MMC (42). The 
second paper was similar in design, but these subjects 
(292 eyes) had not had previous cataract surgery (43). 
Success based on IOP at 3 years was higher in the group 
that had trabeculectomy in phakic eyes. It should be 
noted that the group that had had previous cataract 
surgery, some of the surgery was performed by scleral 
tunnel (as opposed to clear corneal surgery) and this may 
be why the results were worse in the pseudophakic 
group. These studies imply that previous conjunctival 
incisional surgery does indeed have a negative impact on 
subsequent trabeculectomy. A more recent study found 
that, if trabeculectomy following clear corneal 
phacoemulsification surgery is compared to 
trabeculectomy in phakic eyes, success rates are similar 
(44). 
  There is some evidence that prescribing a course of 
topical steroid medication prior to commencing 
trabeculectomy can reduce this priming (45). This has to 
be tempered with the fact that glaucoma patients are 
more prone to the steroid response and hence will need 
to be monitored for this. Furthermore, consideration 
should be given to prescribing NSAIDS or steroid 
medication less associated with the steroid response 
(e.g. g.fluorometholone or g.loteprednoletabonate 
0.5%). 
  However, it must be recognised that following cataract 
surgery, not all cases will achieve adequate IOP lowering 
and some may need glaucoma surgery subsequently. If 
this is necessary, it may be preferable to wait until the 
eye is stable before performing trabeculectomy. Cataract 
surgery causes significant amounts of inflammation in 
the anterior chamber, which is why steroid drops are 
prescribed routinely postoperatively. This inflammation, 
(presumably consisting of lens protein products, blood, 
breakdown of the blood aqueous barrier etc.,) could 
conceivably elicit more scarring if trabeculectomy is 
carried out soon after cataract surgery. Siriwardena et al. 
compared flare (using a flare meter) in the anterior 
chamber after phacoemulsification/IOL to flare after 
trabeculectomy (46). They found flare can last up to 6 
months after routine phacoemulsification as opposed to 
one month after trabeculectomy. This implies that if 
trabeculectomy needs to be performed after cataract 
surgery, it may be preferable to wait 6 months, or maybe 
prescribe more intensive post-operative steroid drops.   
  In cases where there is minimal or no cataract, 
trabeculectomy surgery can be performed if the IOP is 
uncontrolled. The surgery will be on an eye which has 
had no previous surgical trauma and therefore should 
result in less fibrosis at the surgical site (compared to 
 
 
Med Hypothesis Discov Innov Ophthalmol. 2014 Spring;3(1)  
 
25 CATARACTS AND MEDICALLY UNCONTROLLED GLAUCOMA 
pseudophakic eyes for example). However, there is good 
evidence that trabeculectomy causes cataracts. A study 
from Singapore found 66% of subjects had a worsening 
of their lens opacities (by LOCS III units) at 3 years, and 
the majority of these occurred during the first year (47). 
Many other studies have found a similar association (48). 
The cause for increased cataracts after trabeculectomy 
remains unclearalthough a review by Mathew et al., 
postulated on some possible reasons for this association 
(49). As the evidence suggests that cataracts can develop 
or worsen soon after trabeculectomy, subsequent 
cataract surgery is a common occurrence. However, 
performing cataract surgery after trabeculectomy can 
negatively impact bleb function and this effect is 
increased the sooner cataract surgery is performed after 
trabeculectomy. The Singapore group, in a later 
publication, found approximate relative risk (RR) of bleb 
failure (defined as increased IOP) was 3.0 at 6 months, 
1.7 at 1 year and 1.3 at 2 years (50). The implication of 
these findings is that if cataract surgery is performed in 
an eye that’s had a trabeculectomy, it may be preferable 
to wait at least a year, maybe longer, in order to reduce 
the risk of earlier bleb failure. There is good evidence 
that injecting anti-fibrotic agents (such as mitomycin-C 
(MMC), 5-fluorouracil (5-FU) or even bevacizumab 
)intraoperatively during cataract surgery may dampen 
the scarring process (51,52). Another reason to delay 
performing cataract surgery after trabeculectomy is that 
in terms of bleb features such as bleb height, vascularity 
and presence of microcysts, there is evidence that these 
features vary considerable over the first 6 months post-
trabeculectomy, after which a greater degree of stability 
occurs (53). It is tempting to attribute this to the bleb 
remodelling during the first 6 months and therefore 
retains some degree of plasticity. Any trauma (iatrogenic 
otherwise) during this period of plasticity is likely to be 
detrimental to the bleb remodelling process. This 
correlates well with clinical experience in which the first 
3 to 6 months, patients are monitored frequently and 
bleb manipulations are frequently carried out. After 6 
months, this occurs much less frequently. 
 The convenience of performing cataract and 
trabeculectomy surgery together has made 
phacotrabeculectomyvery popular with many surgeons. 
But one has to ask is the convenience (for both patient 
and surgeon) worth it if it has a negative impact in the 
long term lowering effectiveness of the trabeculectomy 
part of the procedure? To see if there is indeed a 
negative impact with phacotrabeculectomy, one needs 
to examine the published data and, if this is lacking, 
examine the procedure from the principle of biological 
plausibility.  
  Looking at the data first, there have been few large; 
long-term prospective studies comparing trabeculectomy 
alone (either in phakic or pseudophakic eyes) to 
combined phacotrabeculectomy, although more are 
needed, given the popularity of these procedures 
worldwide. In a prospective study a group of 44 subjects 
of elderly white patients with POAG had 
phacotrabeculectomy and were matched to a group that 
had trabeculectomy. The trabeculectomy group were 
significantly more successful and effectivethan the 
phacotrabeculectomy group (54).  
  All the surgeries were unaugmented.  In a more recent 
prospective study from Japan comparing the 2 groups 
who all had surgery augmented with MMC, the authors 
also found the trabeculectomy group had significantly 
better success, although the study was only for 1 year 
(55). Kleinmann et al. found similar results in a 
retrospective comparative study of 102 MMC-
augmented eyes, with significantly greater reduction in 
IOP in the trabeculectomy group (56). There have been 
smaller, retrospective studies. Singh et al. published a 
retrospective study of 102 eyes (51 in each group) 
comparing trabeculectomy and phacotrabeculectomy 
(both with post-operative 5-FU injections) and found 
success (defined as IOP more than 16 mmHg at 2 years) 
to be 71% on the trabeculectomy group compared to 
55% in the phacotrabeculectomy group (p<0.01) (57). 
Chang et al. performed a similar study comparing the 2 
groups, although this time intraoperative 5-FU was used 
in both groups (58). Although success at 6 years was 
similar between the groups, there were differences 
between the groups. The trabeculectomy group had 
significantly higher per-operative IOP, was significantly 
younger and had significantly less postoperative 5-FU 
injections compared to the phacotrabeculectomy group. 
In terms of the percentage drop in IOP, it was 
significantly higher in the trabeculectomy alone group 
compared to the combined surgery group (44.6% vs. 
31.2%, p=0.02). There is some evidence to the contrary. 
Vernon’s group published a retrospective study of 37 
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eyes and compared those that had had 
microtrabeculectomy to those that had phaco-
microtrabeculectomy and found no difference at 3 years 
in IOP (59). Murthy et al. also retrospectively compared 
trabeculectomy to phacotrabeculectomy and found that, 
at 2 years, IOP was not significantly different, although 
the trabeculectomy group had a greater reduction in IOP 
compared to the combined surgery group (60), similar to 
the results of the study by Derick et al. in 1998 (61). 
  As can be seen, the data for superiority of 
trabeculectomy over phacotrabeculectomy (or vice 
versa) in terms of IOP control is weak. In these cases, it is 
useful to deconstruct the procedures to determine if 
anything about them could give us an idea as to which 
one is more likely to be successful from a biological 
plausibility perspective. The main difference is that 
phacotrabeculectomy involves removal of the crystalline 
lens at the same time as the trabeculectomy. We know 
that cataract removal results in anterior chamber 
inflammation, and that this can last up to 6 months (46). 
We also know that the earlier one performs cataract 
surgery after trabeculectomy, the earlier trabeculectomy 
failure occurs (RR of failure if phacoemulsification is 
performed 6 months after trabeculectomy is 3.0, in 
contrast to a RR of 1.3 if the time between surgeries is 2 
years) (50). It could therefore be argued that if the time 
between trabeculectomy and cataract surgery is zero (as 
in combined phacotrabeculectomy), this ought to lead to 
earlier failure. This would presumably be because the 
inflammatory material as a result of the 
phacoemulsification (lens proteins etc.) would 
immediately be passing through the sclerostomy and into 
the sub-tenons space during the early post-operative 
period–precisely the time when the most fibrosis at the 
trabeculectomy site occurs. It has to be emphasised 
again that high quality clinical data for earlier failure in 
phacotrabeculectomy are lacking, but from a biological 
plausibility point of view, this hypothesis does have some 
credibility. 
 
Practical guide on how to manage patients 
with cataract and medically uncontrolled 
glaucoma 
Based on the 3 principles described in the introduction, 
for which some justification has been provided in the 
sections above, a management strategy for patients with 
cataract and medically uncontrolled glaucoma can be 
extrapolated. 
  In almost all cases (see below for exceptions), if there is 
significant cataract (defined qualitatively), it would be 
preferable to perform cataract surgery first, using a clear 
corneal tunnel and avoiding making conjunctival 
incisions. The advantage of this approach is clear for 
subjects with XFG or PACG, in that significant IOP 
lowering can sometimes be achieved. In cases with 
PACG, if there are more than 90 degrees of PAS, 
goniosynechialysis can be performed at the same time as 
the cataract surgery. Even in cases of POAG, it is still 
worth removing the cataract first as this may result in 
IOP lowering in a proportion of cases. Those cases in 
which the IOP is not adequately lowered may need 
subsequent trabeculectomy, although it is advisable to 
wait 6 months before this is performed, if possible. Oral 
acetazolamide may be considered as a temporizing 
measure. It is good practice to inform the patient that 
further glaucoma surgery may be necessary if indicated, 
during the consent process for the cataract surgery. 
Another advantage of performing cataract surgery first 
(as opposed to phacotrabeculectomy) is that, especially 
for subjects with PXF or PACG, the cataract surgery itself 
can be difficult, involving iris hooks for example, or 
increasing complication rates. It is far better to manage 
these cataracts separately rather than in conjunction 
with a trabeculectomy.  
  If there is minimal or no cataract, for patients with 
POAG, trabeculectomy can be performed. Again, it is 
advisable to inform the patient that subsequent cataract 
surgery may be necessary, and if so, it may be preferable 
to delay such surgery for at least a year, to allow the bleb 
morphology to stabilise and to reduce the risk of earlier 
bleb failure. Any cataract surgery, if it is performed, 
ought to be augmented with MMC/5-FU or bevacizumab.  
For cases of PXF or PACG and no lens opacity, it is 
debatable if cataract surgery should be performed before 
the trabeculectomy. The EAGLE study, the results of 
which will be available soon, will help answer this 
question for cases of PACG (62). In most cases, however, 
it would still be advisable to perform cataract surgery 
first, even if there is no cataract. For XFG, the longer one 
waits before performing cataract surgery, the more likely 
it is to encounter problems such as poor dilation and 
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zonular instability. In addition, the data suggests that 
removing the lens can reduce the risk of further IOP rises, 
as discussed previously. For subjects with PACG and no 
cataract, the problem with performing trabeculectomy 
first is that trabeculectomy results in a shallowing of the 
anterior chamber and this shallowing remains even at 5 
years post-procedure (9). If one accepts that at least part 
of the mechanism for IOP rise in PACG is a crowded 
anterior chamber leading to irido-trabecular contact, 
then trabeculectomy alone does not address this 
problem, indeed, it will exacerbate it. Taking out the 
cataract addresses the problem of a crowded anterior 
chamber and may lower IOP in many cases. It is safer to 
perform a trabeculectomy in a pseudophakic eye than in 
a phakic eye with a shallow anterior chamber. 
Complications such as aqueous misdirection would be 
more likely in the latter scenario. 
  It seems there is little indication or benefit in 
performing combined phacotrabeculectomy. However, 
this view probably over-emphasises the theoretical 
disadvantages of this procedure. One scenario where 
phacotrabeculectomy might be the procedure of choice 
is in patients with high IOP, cataract and advanced 
glaucoma (particularly open angle). In these patients, 
performing cataract surgery first may result in a pressure 
spike which could result in disc ‘wipe-out’ (63). Low IOP 
at all points in the post-operative period is imperative 
and likely to be achieved only with combined surgery. 
Also, in such a patient it is very likely that trabeculectomy 
will be needed to achieve the low target pressure and 
the luxury of waiting 6 months after cataract surgery 
before performing trabeculectomy is not likely to be 
available. Another scenario is if the patient is unable to 
have 2 separate surgeries, due to financial or other 
constraints. Elderly patients with short life-expectancy 
may also fall in to this group although it is dangerous to 
predict life-expectancy based solely on chronological age. 
 
Summary 
Before trabeculectomy surgery is performed, it is 
important that the implications of the surgery are 
thoroughly understood particularly in the long term. 
Other, more straightforward procedures should be 
considered (such as cataract surgery) and a decision 
based on that individual patient, based on age, severity 
of visual field loss, intraocular pressure, rate of 
glaucomatous progression, type of glaucoma and amount 
of cataract needs to be made. In most cases, cataract 
surgery with or without additional procedures such as 
GSL or ECP should be carried out and such surgery should 
avoid conjunctival incisions. For those subjects that go on 
to require trabeculectomy, it’s best to wait at least 6 
months. For patients with POAG and no cataract, 
trabeculectomy can be performed fist, and if subsequent 
cataract surgery is needed, best to wait for at least a year 
and then augment with surgery with an anti-fibrotic 
agent. Combined phacotrabeculectomy should be 
reserved for subjects with high IOP, advance glaucoma 
and cataract or how are unable or unwilling to undergo 
separate procedures. Other techniques to reduce 
scarring during and after trabeculectomy (e.g. 
antimetabolite use, use of releasable sutures, etc.) need 
due consideration also of course to ensure long term IOP 
control, but these are beyond the scope of this review. At 
all times patients need to kept informed of the 
management decisions with appropriate informed 
consent taken. It is also advisable that they are ‘warned’ 
of future procedures that may be necessary in order to 
prepare them mentally. It is hoped that by following this 
management strategy long term IOP control will become 
more likely and the side effects or complications of 
treatment will be minimised. 
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